Background Scarce data comparing real-world outcomes between apixaban and vitamin K
antagonist (VKA) users with nonvalvular atrial fibrillation (NVAF) are available. We sought to …

In the Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation
(ARISTOTLE) trial, apixaban is comparable to a vitamin K antagonist (VKA) in reducing …

Introduction Apixaban has been shown to be superior to warfarin in patients with non-
valvular atrial fibrillation in the randomized ARISTOTLE trial and its use is recommended in …

Background Vitamin K antagonists have been shown to prevent stroke in patients with atrial
fibrillation. However, many patients are not suitable candidates for or are unwilling to receive …

Background Patients with atrial fibrillation who are vitamin K antagonist (VKA)-naive may
have a higher risk of thrombosis and/or bleeding than VKA-experienced patients. Methods …

Background AVERROES, a randomized controlled trial in high-risk patients with atrial
fibrillation, unsuitable for vitamin K antagonist therapy, demonstrated efficacy and safety of …

Aims To compare the effectiveness and safety of off-label underdosed apixaban with on-
label standard dose apixaban in Asian patients with atrial fibrillation (AF). Methods and …

Background Stroke prevention is the main goal of treating patients with atrial fibrillation (AF).
Vitamin-K antagonists (VKAs) present an effective treatment in stroke prevention, however …

Aim: This study aimed to evaluate the risk of major bleeding among two cohorts of
nonvalvular atrial fibrillation patients newly initiating a vitamin K antagonist (VKA) or …

Aim: To compare the risk of stroke, systemic thromboembolism and bleeding, in patients
initiating apixaban or acenocoumarol for the treatment of nonvalvular atrial fibrillation …